Obatoclax (Mesylate)

Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2[1][2]. Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity[3][4].

Product Specifications

CAS Number

[803712-79-0]

Product Name Alternative

GX15-070 (Mesylate)

UNSPSC

12352005

Hazard Statement

H301

Target

Autophagy; Bcl-2 Family; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Autophagy

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/Obatoclax.html

Purity

99.85

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

COC1=CC(C2=CC3=C(C=CC=C3)N2)=N/C1=C\C4=C(C=C(N4)C)C.CS(=O)(O)=O

Molecular Formula

C21H23N3O4S

Molecular Weight

413.49

Precautions

H301

References & Citations

[1]Or CR, et al. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells. Int J Mol Sci. 2016 Dec 27;18 (1) .|[2]Nguyen M, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A. 2007 Dec 4;104 (49) :19512-7. Epub 2007 Nov 26.|[3]Sulkshane P, et al. BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells. Oncotarget. 2016 Aug 5;8 (36) :60060-60079.|[4]Ehrenkaufer G, et al. Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity. PLoS Negl Trop Dis. 2020 Mar 20;14 (3) :e0008150.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Phase 3

Isoform

Bcl-2; Bcl-B; Bcl-W; Bcl-xL; Mcl-1

Citation 01

Am J Cancer Res. 2019 Mar 1;9 (3) :546-561.|Biomed Pharmacother. 2020 Sep;129:110371.|bioRxiv. 2024 Jul 25.|Cancer Lett. 2023 Feb 1:554:216028.|Drug Deliv Transl Res. 2025 Oct 29.|iScience. 2022 Sep 16;25 (9) :104925.|Norwegian University of Science and Technology. Department of Clinical and Molecular Medicine. 2021 Oct.|Sci Rep. 2019 Sep 24;9 (1) :13786.|Viruses. 2020 Oct 18;12 (10) :1178.|ACS Infect Dis. 2023 Nov 10;9 (11) :2105-2118.|Acta Pharmacol Sin. 2021 Aug;42 (8) :1298-1310.|Departamento de Biotecnología - Departament de Biotecnologia. 2020 Sep 7.